Kidney disease in the setting of HIV infection

conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Conference Participants

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

Original languageEnglish (US)
Pages (from-to)753-760
Number of pages8
JournalKidney International
Volume93
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Kidney Diseases
HIV Infections
HIV
Kidney
AIDS-Associated Nephropathy
Immune Complex Diseases
Pathology
Focal Segmental Glomerulosclerosis
Nephrology
Practice Management
Opportunistic Infections
Natural History
Practice Guidelines
Population
Communicable Diseases
Guidelines
Wounds and Injuries
Therapeutics

Keywords

  • antiretroviral therapy
  • APOL1
  • CKD progression
  • HIV
  • immune complex kidney disease
  • podocytopathy
  • renal pathology

ASJC Scopus subject areas

  • Nephrology

Cite this

Kidney disease in the setting of HIV infection : conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. / Conference Participants.

In: Kidney International, Vol. 93, No. 3, 01.03.2018, p. 753-760.

Research output: Contribution to journalArticle

@article{ea37c3dc76f047bdbf933985c0a6bf4a,
title = "Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
abstract = "HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.",
keywords = "antiretroviral therapy, APOL1, CKD progression, HIV, immune complex kidney disease, podocytopathy, renal pathology",
author = "{Conference Participants} and Swanepoel, {Charles R.} and Atta, {Mohamed G.} and D'Agati, {Vivette D.} and Estrella, {Michelle M.} and Fogo, {Agnes B.} and Saraladevi Naicker and Post, {Frank A.} and Nicola Wearne and Winkler, {Cheryl A.} and Michael Cheung and Wheeler, {David C.} and Winkelmayer, {Wolfgang C.} and Wyatt, {Christina M.} and Ali Abu-Alfa and Dwomoa Adu and Agodoa, {Lawrence Y.} and Alpers, {Charles E.} and Arogundade, {Fatiu A.} and Gloria Ashuntantang and Bagnis, {Corinne I.} and Raj Bhimma and Isabelle Brocheriou and Cohen, {Arthur H.} and Karen Cohen and Cook, {H. Terence} and {de Seigneux}, Sophie and June Fabian and Finkelstein, {Fredric O.} and Mark Haas and Lisa Hamzah and Hendry, {Bruce M.} and Valentine Imonje and Jennette, {J. Charles} and Kimmel, {Paul L.} and Klotman, {Mary E.} and Klotman, {Paul E.} and Larsen, {Chris P.} and McCulloch, {Mignon I.} and Pulane Mosiane and Nast, {Cynthia C.} and Okpechi, {Ikechi G.} and Ray, {Patricio E.} and Rosenberg, {Avi Z.} and Ross, {Michael J.} and Lene Ryom and Luan Truong and Ifeoma Ulasi and Liffert Vogt and Martin Zeier",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.kint.2017.11.007",
language = "English (US)",
volume = "93",
pages = "753--760",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Kidney disease in the setting of HIV infection

T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

AU - Conference Participants

AU - Swanepoel, Charles R.

AU - Atta, Mohamed G.

AU - D'Agati, Vivette D.

AU - Estrella, Michelle M.

AU - Fogo, Agnes B.

AU - Naicker, Saraladevi

AU - Post, Frank A.

AU - Wearne, Nicola

AU - Winkler, Cheryl A.

AU - Cheung, Michael

AU - Wheeler, David C.

AU - Winkelmayer, Wolfgang C.

AU - Wyatt, Christina M.

AU - Abu-Alfa, Ali

AU - Adu, Dwomoa

AU - Agodoa, Lawrence Y.

AU - Alpers, Charles E.

AU - Arogundade, Fatiu A.

AU - Ashuntantang, Gloria

AU - Bagnis, Corinne I.

AU - Bhimma, Raj

AU - Brocheriou, Isabelle

AU - Cohen, Arthur H.

AU - Cohen, Karen

AU - Cook, H. Terence

AU - de Seigneux, Sophie

AU - Fabian, June

AU - Finkelstein, Fredric O.

AU - Haas, Mark

AU - Hamzah, Lisa

AU - Hendry, Bruce M.

AU - Imonje, Valentine

AU - Jennette, J. Charles

AU - Kimmel, Paul L.

AU - Klotman, Mary E.

AU - Klotman, Paul E.

AU - Larsen, Chris P.

AU - McCulloch, Mignon I.

AU - Mosiane, Pulane

AU - Nast, Cynthia C.

AU - Okpechi, Ikechi G.

AU - Ray, Patricio E.

AU - Rosenberg, Avi Z.

AU - Ross, Michael J.

AU - Ryom, Lene

AU - Truong, Luan

AU - Ulasi, Ifeoma

AU - Vogt, Liffert

AU - Zeier, Martin

PY - 2018/3/1

Y1 - 2018/3/1

N2 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

AB - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.

KW - antiretroviral therapy

KW - APOL1

KW - CKD progression

KW - HIV

KW - immune complex kidney disease

KW - podocytopathy

KW - renal pathology

UR - http://www.scopus.com/inward/record.url?scp=85041607294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041607294&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.11.007

DO - 10.1016/j.kint.2017.11.007

M3 - Article

VL - 93

SP - 753

EP - 760

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -